journal article·2023-07

Glucocorticoid-loaded pH/ROS dual-responsive nanoparticles alleviate joint destruction by downregulating the NF-κB signaling pathway

Yanzhu Lu, Jiangling Zhou, Qianmei Wang, Juan Cai, Bo Yu, Qijie Dai, Ying Bao, Rui Chen, Zhongrong Zhang, Dinglin Zhang, Tianyong Hou

Acta Biomaterialia· Volume 164
Publisher page

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease causing severe symptoms that are difficult to treat. Nano-drug delivery system is recognized as a promising strategy for management of RA. However, how to thoroughly release payloads from nanoformulations and synergistic therapy of RA needs to be further investigated. To address this issue, a pH and reactive oxygen species (ROS) dual-responsive, methylprednisolone (MPS)-loaded and arginine-glycine-aspartic acid (RGD)-modified nanoparticles (NPs) was fabricated using phytochemical and ROS-responsive moiety co-modified α-cyclodextrin (α-CD) as a carrier. In vitro and in vivo experiments verified that the pH/ROS dual-responsive nanomedicine could be efficiently internalized by activated macrophages and synovial cells, and the released MPS could promote transformation of M1-type macrophages into M2 phenotype, thereby down-regulating pro-inflammatory cytokines. In vivo experiments demonstrated that the pH/ROS dual-responsive nanomedicine was remarkably accumulated in the inflamed joints of mice with collagen-induced arthritis (CIA). The accumulated nanomedicine could obviously relieve joint swelling and cartilage destruction without obvious adverse effects. Importantly, the expression of interleukin-6 and tumor necrosis factor-α in the joints of CIA mice were significantly inhibited by the pH/ROS dual-responsive nanomedicine in comparison with free drug and non-targeted counterparts. In addition, the expression of the NF-κB signaling pathway molecule P65 was also significantly decreased by nanomedicine-treatment. Our results reveal that MPS-loaded pH/ROS dual-responsive NPs can effectively alleviate joint destruction via down-regulation of the NF-κB signaling pathway. STATEMENT OF SIGNIFICANCE: Nanomedicine is recognized as an attractive method for the targeting treatment of rheumatoid arthritis (RA). To thorough release of payloads from nanoformulations and synergistic therapy of RA, herein, a phytochemical and ROS-responsive moiety co-modified α-cyclodextrin was used as a pH/ROS dual-responsive carrier to encapsulate methylprednisolone to manage RA. The fabricated nanomedicine can effectively release its payloads under pH and/or ROS microenvironment, and the released drugs dramatically promote transformation of M1-type macrophages into M2 phenotype to reduce the release of pro-inflammatory cytokines. The prepared nanomedicine also obviously decreased the NF-κB signaling pathway molecule P65 expression in the joints, thereby down-regulating pro-inflammatory cytokines expression to alleviate joint swelling and cartilage destruction. We provided a candidate for the targeting treatment of RA.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. One year in review 2017: pathogenesis of rheumatoid arthritis
2. Novel treatment strategies in rheumatoid arthritis10.1016/S0140-6736(17)31491-5 ↗
3. One year in review 2018: pathogenesis of rheumatoid arthritis
4. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis10.1016/j.intimp.2019.03.008 ↗
5. The many facets of macrophages in rheumatoid arthritis10.1016/j.bcp.2019.03.029 ↗
6. Managing macrophages in rheumatoid arthritis by reform or removal10.1007/s11926-012-0272-4 ↗
7. Targeted therapy of rheumatoid arthritis via macrophage repolarization10.1080/10717544.2021.2000679 ↗
8. Efficacy of Xixiancao (Herba Siegesbeckiae Orientalis) on interactions between nuclear factor kappa-B and inflammatory cytokines in inflammatory reactions of rat synovial cells induced by sodium urate
9. Panaxynol induces fibroblast-like synovial cell apoptosis, inhibits proliferation and invasion through TLR4/NF-kappaB pathway to alleviate rheumatoid arthritis10.1016/j.intimp.2021.108321 ↗
10. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-alpha secretion10.1007/s000110050222 ↗
11. Targets of glucocorticoid action on TNF-alpha release by macrophages10.1007/PL00012387 ↗
12. Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis10.1136/annrheumdis-2022-222338 ↗
13. An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis10.1080/14740338.2019.1615052 ↗
14. The multiple facets of glucocorticoid action in rheumatoid arthritis10.1038/nrrheum.2012.166 ↗
15. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics10.1016/j.jconrel.2019.11.008 ↗
16. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy10.1016/j.jconrel.2019.04.027 ↗
17. Reactive oxygen species-regulating strategies based on nanomaterials for disease treatment10.1002/advs.202002797 ↗
18. Rheumatoid arthritis microenvironment insights into treatment effect of nanomaterials10.1016/j.nantod.2021.101358 ↗
19. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
20. Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review10.1016/j.autrev.2019.102397 ↗
21. HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis10.1038/s41467-019-12163-z ↗
22. Au@polydopamine nanoparticles/tocilizumab composite as efficient scavengers of oxygen free radicals for improving the treatment of rheumatoid arthritis10.1016/j.msec.2020.111434 ↗
23. Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment10.1021/acsnano.8b08785 ↗
24. ROS-responsive berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria
25. Reactive oxygen species-responsive dendritic cell-derived exosomes for rheumatoid arthritis10.1016/j.actbio.2021.04.026 ↗
26. Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy10.1016/j.actbio.2020.11.027 ↗
27. pH-sensitive polymeric micelles as the methotrexate carrier for targeting rheumatoid arthritis10.1007/s13233-020-8072-6 ↗
28. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy
29. Modular acid-activatable acetone-based ketal-linked nanomedicine by dexamethasone prodrugs for enhanced anti-rheumatoid arthritis with low side effects10.1021/acs.nanolett.9b05340 ↗
30. Cinnamaldehyde and eugenol attenuates collagen induced arthritis via reduction of free radicals and pro-inflammatory cytokines10.1016/j.phymed.2018.09.004 ↗
31. Cinnamaldehyde attenuates the progression of rheumatoid arthritis through down-regulation of PI3K/AKT signaling pathway10.1007/s10753-020-01246-5 ↗
32. Cinnamaldehyde suppresses NLRP3 derived IL-1beta via activating succinate/HIF-1 in rheumatoid arthritis rats10.1016/j.intimp.2020.106570 ↗
33. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway10.1016/j.jsps.2020.07.011 ↗
34. Anti-oxidant and anti-inflammatory effects of cinnamaldehyde and eugenol on mononuclear cells of rheumatoid arthritis patients10.1016/j.ejphar.2019.02.031 ↗
35. Reactive oxygen species-responsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2/TNF-alpha/BAFF signaling pathway10.1016/j.biomaterials.2019.119730 ↗
36. Antibiotic-loaded reactive oxygen species-responsive nanomedicine for effective management of chronic bacterial prostatitis10.1016/j.actbio.2022.02.044 ↗
37. Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment10.1080/10717544.2021.1963351 ↗
38. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles10.1186/s12951-019-0537-4 ↗
39. Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis10.4103/1735-5362.272534 ↗
40. Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment
41. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases10.1016/j.nano.2015.04.015 ↗
42. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
43. Targeting strategies for tissue-specific drug delivery10.1016/j.cell.2020.02.001 ↗
44. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery10.1039/C2CS35265F ↗
45. The role of neutrophils in rheumatic disease-associated vascular inflammation10.1038/s41584-021-00738-4 ↗
46. The dichotomized role for acid sensing ion channels in musculoskeletal pain and inflammation10.1016/j.neuropharm.2014.12.013 ↗
47. Surface engineering of nanomaterials with phospholipid-polyethylene glycol-derived functional conjugates for molecular imaging and targeted therapy10.1016/j.biomaterials.2019.119646 ↗
48. Advance in bone destruction participated by JAK/STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors10.1016/j.intimp.2022.109095 ↗
49. Macrophage M1/M2 polarization10.1016/j.ejphar.2020.173090 ↗
50. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis10.3389/fimmu.2022.867260 ↗
51. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-kappaB pathway10.1016/j.intimp.2017.01.010 ↗
52. Anti-rheumatoid arthritis effects of iridoid glucosides from Lamiophlomis rotata (Benth.) kudo on adjuvant-induced arthritis in rats by OPG/RANKL/NF-kappaB signaling pathways10.1016/j.jep.2020.113402 ↗
53. Difficult to treat' rheumatoid arthritis: current position and considerations for next steps10.1136/rmdopen-2022-002387 ↗